Copyright Reports & Markets. All rights reserved.

Global Biosimilars of Rituximab Market Research Report 2021

Buy now

1 Biosimilars of Rituximab Market Overview

  • 1.1 Product Overview and Scope of Biosimilars of Rituximab
  • 1.2 Biosimilars of Rituximab Segment by Type
    • 1.2.1 Global Biosimilars of Rituximab Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 500mg
    • 1.2.3 100mg
    • 1.2.4 Other
  • 1.3 Biosimilars of Rituximab Segment by Application
    • 1.3.1 Global Biosimilars of Rituximab Sales Comparison by Application: (2021-2027)
    • 1.3.2 Hospital Pharmacy
    • 1.3.3 Retail Pharmacy
  • 1.4 Global Biosimilars of Rituximab Market Size Estimates and Forecasts
    • 1.4.1 Global Biosimilars of Rituximab Revenue 2016-2027
    • 1.4.2 Global Biosimilars of Rituximab Sales 2016-2027
    • 1.4.3 Biosimilars of Rituximab Market Size by Region: 2016 Versus 2021 Versus 2027

2 Biosimilars of Rituximab Market Competition by Manufacturers

  • 2.1 Global Biosimilars of Rituximab Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Biosimilars of Rituximab Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Biosimilars of Rituximab Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Biosimilars of Rituximab Manufacturing Sites, Area Served, Product Type
  • 2.5 Biosimilars of Rituximab Market Competitive Situation and Trends
    • 2.5.1 Biosimilars of Rituximab Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Biosimilars of Rituximab Players Market Share by Revenue
    • 2.5.3 Global Biosimilars of Rituximab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Biosimilars of Rituximab Retrospective Market Scenario by Region

  • 3.1 Global Biosimilars of Rituximab Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.2 Global Biosimilars of Rituximab Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.3 North America Biosimilars of Rituximab Market Facts & Figures by Country
    • 3.3.1 North America Biosimilars of Rituximab Sales by Country
    • 3.3.2 North America Biosimilars of Rituximab Revenue by Country
    • 3.3.3 United States
    • 3.3.4 Canada
  • 3.4 Europe Biosimilars of Rituximab Market Facts & Figures by Country
    • 3.4.1 Europe Biosimilars of Rituximab Sales by Country
    • 3.4.2 Europe Biosimilars of Rituximab Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Biosimilars of Rituximab Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Biosimilars of Rituximab Sales by Region
    • 3.5.2 Asia Pacific Biosimilars of Rituximab Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
  • 3.6 Latin America Biosimilars of Rituximab Market Facts & Figures by Country
    • 3.6.1 Latin America Biosimilars of Rituximab Sales by Country
    • 3.6.2 Latin America Biosimilars of Rituximab Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Biosimilars of Rituximab Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Biosimilars of Rituximab Sales by Country
    • 3.7.2 Middle East and Africa Biosimilars of Rituximab Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Biosimilars of Rituximab Historic Market Analysis by Type

  • 4.1 Global Biosimilars of Rituximab Sales Market Share by Type (2016-2021)
  • 4.2 Global Biosimilars of Rituximab Revenue Market Share by Type (2016-2021)
  • 4.3 Global Biosimilars of Rituximab Price by Type (2016-2021)

5 Global Biosimilars of Rituximab Historic Market Analysis by Application

  • 5.1 Global Biosimilars of Rituximab Sales Market Share by Application (2016-2021)
  • 5.2 Global Biosimilars of Rituximab Revenue Market Share by Application (2016-2021)
  • 5.3 Global Biosimilars of Rituximab Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Amgen
    • 6.1.1 Amgen Corporation Information
    • 6.1.2 Amgen Description and Business Overview
    • 6.1.3 Amgen Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Amgen Biosimilars of Rituximab Product Portfolio
    • 6.1.5 Amgen Recent Developments/Updates
  • 6.2 AryoGen Pharmed
    • 6.2.1 AryoGen Pharmed Corporation Information
    • 6.2.2 AryoGen Pharmed Description and Business Overview
    • 6.2.3 AryoGen Pharmed Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 AryoGen Pharmed Biosimilars of Rituximab Product Portfolio
    • 6.2.5 AryoGen Pharmed Recent Developments/Updates
  • 6.3 Biocad
    • 6.3.1 Biocad Corporation Information
    • 6.3.2 Biocad Description and Business Overview
    • 6.3.3 Biocad Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Biocad Biosimilars of Rituximab Product Portfolio
    • 6.3.5 Biocad Recent Developments/Updates
  • 6.4 Cadila Pharmaceuticals
    • 6.4.1 Cadila Pharmaceuticals Corporation Information
    • 6.4.2 Cadila Pharmaceuticals Description and Business Overview
    • 6.4.3 Cadila Pharmaceuticals Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Cadila Pharmaceuticals Biosimilars of Rituximab Product Portfolio
    • 6.4.5 Cadila Pharmaceuticals Recent Developments/Updates
  • 6.5 Celltrion
    • 6.5.1 Celltrion Corporation Information
    • 6.5.2 Celltrion Description and Business Overview
    • 6.5.3 Celltrion Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Celltrion Biosimilars of Rituximab Product Portfolio
    • 6.5.5 Celltrion Recent Developments/Updates
  • 6.6 Dr Reddy’s Laboratories
    • 6.6.1 Dr Reddy’s Laboratories Corporation Information
    • 6.6.2 Dr Reddy’s Laboratories Description and Business Overview
    • 6.6.3 Dr Reddy’s Laboratories Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 Dr Reddy’s Laboratories Biosimilars of Rituximab Product Portfolio
    • 6.6.5 Dr Reddy’s Laboratories Recent Developments/Updates
  • 6.7 Teva
    • 6.6.1 Teva Corporation Information
    • 6.6.2 Teva Description and Business Overview
    • 6.6.3 Teva Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Teva Biosimilars of Rituximab Product Portfolio
    • 6.7.5 Teva Recent Developments/Updates
  • 6.8 Hetero Group
    • 6.8.1 Hetero Group Corporation Information
    • 6.8.2 Hetero Group Description and Business Overview
    • 6.8.3 Hetero Group Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Hetero Group Biosimilars of Rituximab Product Portfolio
    • 6.8.5 Hetero Group Recent Developments/Updates
  • 6.9 Innovent Biologics
    • 6.9.1 Innovent Biologics Corporation Information
    • 6.9.2 Innovent Biologics Description and Business Overview
    • 6.9.3 Innovent Biologics Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Innovent Biologics Biosimilars of Rituximab Product Portfolio
    • 6.9.5 Innovent Biologics Recent Developments/Updates
  • 6.10 Intas Biopharmaceuticals
    • 6.10.1 Intas Biopharmaceuticals Corporation Information
    • 6.10.2 Intas Biopharmaceuticals Description and Business Overview
    • 6.10.3 Intas Biopharmaceuticals Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 Intas Biopharmaceuticals Biosimilars of Rituximab Product Portfolio
    • 6.10.5 Intas Biopharmaceuticals Recent Developments/Updates
  • 6.11 Mylan
    • 6.11.1 Mylan Corporation Information
    • 6.11.2 Mylan Biosimilars of Rituximab Description and Business Overview
    • 6.11.3 Mylan Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Mylan Biosimilars of Rituximab Product Portfolio
    • 6.11.5 Mylan Recent Developments/Updates
  • 6.12 Probiomed
    • 6.12.1 Probiomed Corporation Information
    • 6.12.2 Probiomed Biosimilars of Rituximab Description and Business Overview
    • 6.12.3 Probiomed Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Probiomed Biosimilars of Rituximab Product Portfolio
    • 6.12.5 Probiomed Recent Developments/Updates
  • 6.13 TRPharma
    • 6.13.1 TRPharma Corporation Information
    • 6.13.2 TRPharma Biosimilars of Rituximab Description and Business Overview
    • 6.13.3 TRPharma Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 TRPharma Biosimilars of Rituximab Product Portfolio
    • 6.13.5 TRPharma Recent Developments/Updates
  • 6.14 Zenotech Laboratories
    • 6.14.1 Zenotech Laboratories Corporation Information
    • 6.14.2 Zenotech Laboratories Biosimilars of Rituximab Description and Business Overview
    • 6.14.3 Zenotech Laboratories Biosimilars of Rituximab Sales, Revenue and Gross Margin (2016-2021)
    • 6.14.4 Zenotech Laboratories Biosimilars of Rituximab Product Portfolio
    • 6.14.5 Zenotech Laboratories Recent Developments/Updates

7 Biosimilars of Rituximab Manufacturing Cost Analysis

  • 7.1 Biosimilars of Rituximab Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Biosimilars of Rituximab
  • 7.4 Biosimilars of Rituximab Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Biosimilars of Rituximab Distributors List
  • 8.3 Biosimilars of Rituximab Customers

9 Biosimilars of Rituximab Market Dynamics

  • 9.1 Biosimilars of Rituximab Industry Trends
  • 9.2 Biosimilars of Rituximab Growth Drivers
  • 9.3 Biosimilars of Rituximab Market Challenges
  • 9.4 Biosimilars of Rituximab Market Restraints

10 Global Market Forecast

  • 10.1 Biosimilars of Rituximab Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Biosimilars of Rituximab by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Biosimilars of Rituximab by Type (2022-2027)
  • 10.2 Biosimilars of Rituximab Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Biosimilars of Rituximab by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Biosimilars of Rituximab by Application (2022-2027)
  • 10.3 Biosimilars of Rituximab Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Biosimilars of Rituximab by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Biosimilars of Rituximab by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    500mg
    100mg
    Other

    Segment by Application
    Hospital Pharmacy
    Retail Pharmacy

    By Region
    North America
    United States
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Amgen
    AryoGen Pharmed
    Biocad
    Cadila Pharmaceuticals
    Celltrion
    Dr Reddy’s Laboratories
    Teva
    Hetero Group
    Innovent Biologics
    Intas Biopharmaceuticals
    Mylan
    Probiomed
    TRPharma
    Zenotech Laboratories

    Buy now